BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
DetailsGuangzhou, China / Jeddah, Saudi Arabia – September 15,2025 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars and Jamjoom PharmaceuticalsFactory Company (Jamjoom Pharma), one of the fastest-growing p...
Guangzhou,China– September 10, 2025 – Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovative therapies and biosimilars, today announced that the MHRA hasapproved Qletli ® (adalimumab), a biosimilar of Humira ® ,for the treatment of r...
BAT2206 is Bio-Thera Solutions’ third EC approvedproduct Guangzhou, China– August , 2024 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeveloping a pipeline of innovative therapies and biosimilars, today announcedthat the EC has approved BAT2206 (ustekinum...
